These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 22435507

  • 1. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.
    Han XF, Wang QX, Liu Y, You ZR, Bian ZL, Qiu DK, Ma X.
    J Dig Dis; 2012 Apr; 13(4):219-24. PubMed ID: 22435507
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
    Zhang Y, Li S, He L, Wang F, Chen K, Li J, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Xia Y, Zhou Y, Lu J, Guo C.
    Drug Des Devel Ther; 2015 Apr; 9():2757-66. PubMed ID: 26045661
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
    Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, Clark V, Firpi RJ, Morelli G, Soldevila-Pico C, Lindor K.
    Aliment Pharmacol Ther; 2011 Jan; 33(2):235-42. PubMed ID: 21083674
    [Abstract] [Full Text] [Related]

  • 5. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, Feld JJ.
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D, Ren P, Guo G, Liu Y, Yang C, Zheng L, Jia G, Deng J, Sun R, Wang X, Zhou X, Shang Y, Han Y.
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
    Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, Sun R, Wang X, Guo C, Shang Y, Han Y.
    Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC.
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ, Lv DX, Jia W, Li J, Deng YQ, Wang Y, Yu M, Wang GQ.
    Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
    [Abstract] [Full Text] [Related]

  • 16. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
    Angulo P, Jorgensen RA, Lindor KD.
    Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
    [Abstract] [Full Text] [Related]

  • 17. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW, Lee JH, Kim MA, Leem G, Kim SW, Chang Y, Lee HY, Yoon JS, Park JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH.
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [Abstract] [Full Text] [Related]

  • 18. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
    Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H.
    J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
    [Abstract] [Full Text] [Related]

  • 19. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R, Tur-Kaspa R.
    J Clin Gastroenterol; 2010 Jun; 44(5):371-3. PubMed ID: 19881358
    [Abstract] [Full Text] [Related]

  • 20. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M, Men R, Fan X, Shen Y, Ni P, Hu Z, Yang L.
    Dig Dis; 2021 Jun; 39(4):366-374. PubMed ID: 33238269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.